Management of Hepatocellular Carcinoma in Japan: Current Trends
Author:
Publisher
S. Karger AG
Subject
Oncology,Hepatology
Reference11 articles.
1. Kudo M, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, et al.; Liver Cancer Study Group of Japan. Survival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan. Liver Cancer. 2016 Jul;5(3):190–7.
2. Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, et al.; SILIUS study group. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424–32.
3. Kudo M. Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer. 2012 Sep;1(2):62–70.
4. Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, et al.; Liver Cancer Study Group of Japan. JSH Consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer. 2014 Oct;3(3-4):458–68.
5. Kitai S, Kudo M, Nishida N, Izumi N, Sakamoto M, Matsuyama Y, et al.; Liver Cancer Study Group of Japan. Survival benefit of locoregional treatment for hepatocellular carcinoma with advanced liver cirrhosis. Liver Cancer. 2016 Jul;5(3):175–89.
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Novel Clinical prognostic model to predict survival in hepatocellular carcinoma after LR or LT should be considered including biological characteristics and inflammation score;2023-10-17
2. Telephone follow‐up contributes to improving adherence and treatment duration in patients with hepatocellular carcinoma treated with lenvatinib;Journal of Gastroenterology and Hepatology;2023-03-16
3. Atezolizumab plus bevacizumab versus lenvatinib as first-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis;Clinical and Experimental Hepatology;2023
4. Liver;Stereotactic Body Radiation Therapy;2023
5. Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis;Targeted Oncology;2022-10-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3